A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07549646 |
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07468071 |
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments |
RECRUITING | PHASE1/PHASE2 |
| NCT07440290 |
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. |
RECRUITING | PHASE2/PHASE3 |
| NCT07131059 |
MRD-positive AML Clinical Study |
RECRUITING | NA |
| NCT07110246 |
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas |
RECRUITING | PHASE2 |
| NCT06475989 |
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer |
RECRUITING | PHASE3 |
| NCT05358249 |
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05180825 |
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy |
RECRUITING | PHASE2 |
| NCT04940052 |
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04675710 |
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
